Age alone should not preclude the use of immune checkpoint inhibitors in people with cancer aged 80 years or more, say researchers who found promising efficacy and tolerability of single-agent therapy in this patient population.
A large single-center study has found an association between immune checkpoint inhibitor use and an increased incidence of venous thromboembolism in people with cancer.
A patient-derived tumor fragment platform has allowed close examination of the early immunologic responses to PD-1 blockade, revealing a relationship between immune cell reactivation and clinical response.
Chinese researchers have used a combination of long noncoding RNA signatures and cytotoxic T-lymphocyte tumor infiltration to identify four distinct immune classes that may predict response to cancer immunotherapy.
Phase 1b/2 study data show that combining the multitargeted tyrosine kinase inhibitor lenvatinib with pembrolizumab could be a promising treatment option for patients with advanced renal cell carcinoma and selected other advanced solid tumor types.
HLA class I evolutionary divergence is associated with response to immune checkpoint inhibitor treatment in people with cancer, show data published in Nature Medicine.